• LTR Pharma secures 33% equity stake in LevOmega at no cost
• LevOmega to develop nature-identical, pharmaceutical-grade omega-3 oil
• Provides LTR exposure to multi-billion-dollar global omega-3 market

LTR Pharma Limited (ASX:LTP) has secured a one-third equity ownership in LevOmega Pty Ltd at no cost to LTR Pharma shareholders. LevOmega has been co-founded by Levur Pty Ltd, Green Blue Health Pty Ltd, and LTR Pharma, with each co-founder contributing distinct strengths - Levur in innovation and product development, Green Blue Health in nutraceutical and health market experience, and LTR Pharma in pharmaceutical, regulatory, and commercial capability. LevOmega is an Australian operating company focused on the development of nature-identical omega-3 products, with the mission to deliver high-purity, consistent omega-3 ingredients that can be used in both nutritional and pharmaceutical applications. LevOmega has formally entered into an R&D Services and Licensing Agreement with Levur Pty Ltd, under which Levur will provide specialist R&D services and license its proprietary advanced biotechnology platform to LevOmega to advance the development of nature-identical, pharmaceutical-grade Omega-3 oil. This partnership aligns with LTR Pharma's strategy of developing first-in-class therapies for large markets with unmet needs, providing the company with exposure to the multi-billion-dollar global omega-3 market, which is facing supply constraints due to overfishing, pollution, and declining yields.

LevOmega's development pathway will progress through technical validation, pilot-scale production, and ultimately commercial launch, supplying pharmaceutical-grade omega-3 ingredients to pharmaceutical, nutraceutical, and functional food manufacturers.